GMAB · Genmab
AI read · Good for GMAB
The AI's read
Growth came from across Genmab’s product range, including Epkinly. The trial results may support broader use of its medicines, but they are not approvals. Genmab kept its 2026 revenue forecast and expects to finish in the upper part of its range. Drug programs can still fail or run late, but the call reports no setback to counter the growth and trial results.